No. 2: Inhibitex (INHX)
It's fitting that the two top-performing biopharmaceutical stocks of 2011 are both focused on developing new drugs for hepatitis C. It's also telling that Inhibitex, clocking in at No. 2 this year, is still years away from (possibly) pushing a drug across the finish line and making it to the market.
The stock: Inhibitex shares are up 302% as of Dec. 16.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts